Use of buspirone and fluoxetine for breathing problems in Rett syndrome.

Abstract

Rett syndrome is a severe neurodevelopmental disease with a prevalence of 0.88 per 10,000 girls aged 5-18 years, and is often caused by mutations in methyl-cytosine-phosphate-guanine (CpG)-binding protein 2. Disorder of respiratory control is a prominent feature of Rett syndrome. Brainstem serotoninergic neurons are known to play an important role in the arrangement of breathing rhythm and pattern. We present a patient whose severe hyperventilation and apneic attacks resolved with the concomitant treatment of fluoxetine and buspirone. To our knowledge, we describe the first patient with Rett syndrome to receive fluoxetine for respiratory problems.

• Authors: Sarenur Gökben, Ulkü Akyol Ardıç, Gül Serdaroğlu
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 46 Issue 3 Pg. 192-4 (Mar 2012) ISSN: 1873-5150 [Electronic] United States
• PMID: 22353299 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2012 Elsevier Inc. All rights reserved.

Chemical References

• Serotonin Receptor Agonists
• Serotonin Uptake Inhibitors
• Fluoxetine
• Buspirone

Topics

• Apnea (drug therapy, etiology)
• Buspirone (therapeutic use)
• Child
• Female
• Fluoxetine (therapeutic use)
• Humans
• Hyperventilation (drug therapy, etiology)
• Rett Syndrome (complications)
• Serotonin Receptor Agonists (therapeutic use)
• Selective Serotonin Reuptake Inhibitors (therapeutic use)
• Treatment Outcome